Aktie A1JDC2 RAQUALIA PHARMA INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen RaQualia Pharma Inc.

Aktien

A1JDC2

JP3967150008

4579

Markt geschlossen - Japan Exchange
Andere Börsenplätze
 08:00:00 15.05.2024 		% 5 Tage % 1. Jan.
583 JPY -2,51 % Intraday Chart für RaQualia Pharma Inc. -4,27 % -15,26 %
26.03. RaQualia Pharma Inc. (TSE:4579) hat die Übernahme von FIMECS, Inc. von Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership verwaltet von Nissay Capital Co., Ltd, ANRI No. 4 Fund verwaltet von ANRI und anderen abgeschlossen. CI
14.02. RaQualia Pharma Inc. gibt konsolidierte Gewinnprognose für das Jahr bis zum 31. Dezember 2024 ab CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
RaQualia Pharma Inc. completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others.
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024
RaQualia Pharma Inc. agreed to acquire FIMECS, Inc. from Nissay Capital No. 11 Investment Limited Partnership and Nissay Capital Co., Ltd. for ¥4.5 billion.
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023
Constipation Pipeline, Clinical Trials, and Key Companies|Companies-Anji Pharma, Yuhan, Theravance Biopharma
RaQualia Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
RaQualia Pharma Inc. announced that it has received ¥805.6125 million in funding from CVI Investments, Inc.
RaQualia Pharma Inc. announced that it expects to receive Ñ805.6125 million in funding from CVI Investments, Inc.
Raqualia Pharma Inc. Provides Consolidated Earnings Guidance for Year Ending December 31, 2022
RaQualia Pharma : Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (JGAAP)
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022
RaQualia Pharma : (Delayed)Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (JGAAP)
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022
RaQualia Pharma Inc. Provides Earnings Guidance for the Year Ending December 31, 2021
Raqualia Pharma Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2021
RaQualia Pharma Inc. Announces Consolidated Financial Results for the Six Months Ended June 30, 2021
RaQualia Pharma Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2021
RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A1JDC2 Aktie
  4. Nachrichten RaQualia Pharma Inc.
  5. Andere Sprachen